More Topics:
Vertex: The Best Of The Companies Investing In Cystic Fibrosis
Posted February 21, 2012
We Recommend...
By Jessica King Holden
Imagine assembling a child's first bike. After hours of diligently following the instructions, you send your little one off, excited to try it out. Unbeknownst to you, the instructions contained an error and the bike was not assembled correctly. You watch your little one take a tumble off the malfunctioning bike, thankful for helmets, knee pads and band-aides, and vow to fix the problem. Conventional wisdom says one should find the instructions, notify the company to fix their instructions for good and rebuild the bike. For some reason, however, that is not possible at this time.
In the healthcare sector, Cystic Fibrosis (CF) is that child's bike. Unfortunately, the best approach to fix a malfunctioning protein as in the case of CF, (in the medical world known as gene therapy), is simple in theory but has not shown much follow through in actuality. The viable angles being taken by current pharmaceutical companies are focused on attacking other routes than fixing the instructions for good.
Cystic Fibrosis has offered a mix of frustration and excitement in the pharmaceutical sector since the root cause of the disease was discovered. READ FULL ARTICLE HERE
blog comments powered by